Radiopharmaceuticals are precision nuclear medicines used for medical imaging and treatment that allow doctors to diagnose and deliver targeted therapies for diseases such as cancer.

A new discussion paper from MTPConnect, ‘From Mines to Medicines. Australia’s Radiopharmaceuticals Future’ reveals how Australia is ready to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies drive significant investment and rapid expansion. South Australia is identified as the ideal location to lead the development of Australia’s radiopharmaceuticals future, with end-to-end capabilities – from unique mining assets and a robust research ecosystem through to cutting-edge clinical services and specialised workforce.

In this feature length episode, hosts Caroline Duell and Dana Bell, MTPConnect’s Partnerships Director South Australia, speak to experts in South Australia along the supply chain - from mines to medicines including:

• UniSAs Professor Eva Bezak, Deputy Director of the Australian Research Council’s Industrial Transformation Training Centre (ITTC) for Radiation Innovation (Time code: 10.32) on researching new radiopharmaceuticals and building a highly skilled workforce to scale up,

• SAHMRI’s Chady Barkil, Director, Molecular Imaging and Therapy Research Unit (MITRU) (Time code: 35.43) on manufacturing nuclear medicines and the supply chain challenges,

• EntX's Dr Massey de Los Reyes, Principal Scientist and Facilities Manager, on developing technology to transform mining waste into medical isotope production (at Time code: 57.36),

• Novartis ANZ’s Matt Zeller, Country President (Time code: 1.17.03) on how the company is reimagining cancer care with its precision nuclear medicine pipeline,

• Artesian’s Stephanie Morris, Investment Manager (Time code: 1.36.02) discusses the investment activity and interest in the growing radiopharmaceuticals market and,

• Department for Industry, Innovation and Science’s Dr Judy Halliday, Director Innovation and Entrepreneurship (Time code: 1.48.06) outlines South Australia’s strengths as a first mover to unlock the radiopharmaceutical industry opportunity.